|
Abstract Objective: To study the expression of serum monocyte chemoattractant protein (MCP)-1, interleukin(IL)-18, and lipoprotein (LP)a of preeclampsia women with sleep apnea hypopnea syndrome (SAHS). Methods: From March 2016 to March 2018, 60 women with preeclampsia combined with SAHS were selected in group A, 50 women with preeclampsia only were selected in group B, and 50 healthy pregnant women were selected in group C. The levels of MCP-1, IL-18 and LP (a), and the values of sleep apnea hypopnea index (AHI) and the value of the lowest oxygen saturation (LSaO2) of women in three groups were detected, and their significance in group A was analyzed. Results: The serum MCP-1, IL-18, LP(a) levels and AHI value of women in group A were significant higher than those of women in group B and C, but the LSaO2 value was significant lower (P<0.05). The serum MCP-1, IL-18 and LP(a) of women in group B were significant higher than those of women in group C (P<0.05), but there were no significant difference in values of AHI and LSaO2 of women between the group B and group C (P>0.05). Pearson correlation analysis showed that there was a positive correlation between the serum levels of MCP-1, IL-18, LP(a) and the values of AHI and LSaO2 (P<0.05).The logistical regression analysis showed that the serum MCP-1, IL-18 and LP(a) levels were the risk factors for preeclampsia complicated with SAHS (P<0.05).The ROC curve analysis showed that the sensitivity of serum MCP-1 level, IL-18 level and LP(a) level for diagnosing preeclampsia combined with SAHS were 78.5%, 80.5% and 81.0%, respectively. The specificity of serum MCP-1 level, IL-18 level and LP(a) level for diagnosing preeclampsia combined with SAHS were 74.1%, 78.3%, and 75.3%, respectively. Conclusion: The serum MCP-1, IL-18 and LP(a) are involved in the occurrence and development of preeclampsia combined with SAHS, which provides new idea for clinical diagnosis and treatment of preeclampsia combined with SAHS.
|
|
|
|
|
|
